Advances in risk-benefit evaluation using probabilistic simulation methods: An application to the prophylaxis of deep vein thrombosis

Journal of Clinical Epidemiology

Volumn 57, Issue 8, 2004, Pages 795-803

  Lynd, Larry D ^a,b   O'Brien, Bernie J ^a,b  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b 25 Main St W Suite 2000 L8H 1P1 ^*  (Canada)

Author keywords

Data interpretation; Monte Carlo method; Risk; Risk assessment; statistical; Uncertainty

Indexed keywords

ENOXAPARIN; HEPARIN;

ARTICLE; BAYES THEOREM; BIOSTATISTICS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; HUMAN; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

ANTICOAGULANTS; DECISION SUPPORT TECHNIQUES; ENOXAPARIN; HEMORRHAGE; HEPARIN; HUMANS; MONTE CARLO METHOD; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 5644240874     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2003.12.012     Document Type: Article

References (17)

1. Willan A.R., O'Brien B.J., Cook D.J. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trials. 18:1997;121-130
2. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 22:2001;102-110
3. Lesaffre E., Pledger G. A note on the number needed to treat. Control Clin Trials. 20:1999;439-447
4. Stinnett A.A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 18:(2 Suppl):1998;S68-S80
5. Briggs A.H., O'Brien B.J., Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 23:2002;377-401
6. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 17:2000;479-500
7. O'Brien B.J., Drummond M.F., Labelle R.J., Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 32:1994;150-163
8. Willan A.R., O'Brien B.J. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ. 5:1996;297-305. Erratum: Health Econ 1999;8:559
9. Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 6:1997;327-340
10. van Hout B.A., Al M.J., Gordon G.S., Rutten F.F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 3:1994;309-319
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
12. Geerts W.H., Jay R.M., Code K.I., Chen E., Szalai J.P., Saibil E.A., Hamilton P.A. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 335:1996;701-707
13. Black W.C. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 10:1990;212-214
14. O'Brien B.J., Gertsen K., Willan A.R., Faulkner L.A. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ. 11:2002;175-180
15. Briggs A.H., O'Brien B.J. The death of cost-minimization analysis? Health Econ. 10:2001;179-184
16. Guyatt G.H., Sinclair J., Cook D.J., Glasziou P. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. Users' guides to the medical literature: XVI. How to use a treatment recommendation. JAMA. 281:1999;1836-1843
17. Coyle D., Buxton M.J., O'Brien B.J. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 12:2003;421-427